A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Clinical trial NCT02446717 · COMPLETED

Trial details

NCT number: NCT02446717
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Chronic Hepatitis C Hepatitis C Virus HCV Direct-Acting Antiviral Agent (DAA)-Experienced

Start date: 2015-04-01
Primary completion: 2016-12-01
Enrollment: 141

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.